MikroScore
Science-backed ingredient evidence
Moderate Evidence Safety: Likely safe Study dose: 500 mg/day

NMN (Nicotinamide Mononucleotide)

Also known as: Nicotinamide Mononucleotide, β-NMN, NMN-Supplement

Summary Moderate Evidence

NMN is a direct precursor to NAD+. Animal studies are promising — robust human trials are still lacking, and the EU regulatory status is unclear.

EU Health Claims: No approved claims

EFSA has not approved any health claims for NMN. In 2022 the FDA excluded NMN from the dietary supplement category (it was being investigated as a drug). In the EU, NMN is currently classified as a Novel Food — its status remains regulatorily uncertain.

AI Summary

Quick verdict

NMN is a direct precursor to NAD+. Animal studies are promising — robust human trials are still lacking, and the EU regulatory status is unclear.

What the evidence supports

Several small human RCTs show that NMN raises blood NAD+ levels. Whether that translates into health or longevity benefits remains unproven.

What is NOT supported

Long-term safety and rare adverse effects in humans remain insufficiently studied.

EU/EFSA status

Not approved. EFSA has not approved any health claims for NMN. In 2022 the FDA excluded NMN from the dietary su…

Safety

Likely safe

This AI summary is generated from the structured data on this page.

What is NMN?

NMN (Nicotinamide Mononucleotide) is a molecule that serves as a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide) in the body. NAD+ is involved in hundreds of enzymatic reactions — primarily in mitochondrial energy production and DNA damage repair.

The problem: NAD+ levels decline with age. The premise behind NMN supplements is that raising these levels through supplementation can slow ageing processes.

What Do the Studies Actually Show?

What’s supported

  • NMN is absorbed by the body and in small human studies has been associated with higher blood NAD+ levels
  • Animal studies (mice) show striking effects: better muscle function, more energy, longer lifespan
  • Early small human studies show no serious side effects at 250–1,200 mg/day

The problem

  • The leap from mice to humans is especially difficult in ageing research
  • Not a single RCT has shown any effect on lifespan in humans
  • “Raising NAD+ levels” is not a clinical endpoint — it is a biomarker. Whether that rise is clinically meaningful remains unknown
  • The FDA excluded NMN from the supplement category in 2022 because it was being investigated as a pharmaceutical

Bottom line: NMN is scientifically interesting. Marketing it as an anti-ageing miracle goes far beyond what the evidence supports.

Is NMN Safe?

Based on current data: probably safe at short-term doses up to ~1,200 mg/day. A 2022 animal study with NR — a related compound — raised concerns about increased breast cancer risk at high doses. No comparable finding exists for NMN, but long-term human data are completely absent.

Regulatory Status in the EU

NMN is classified as a Novel Food in the EU (Regulation EU 2015/2283). This means products may only be sold if a Novel Food authorisation has been applied for and granted. Many commercially available NMN products operate in a legal grey zone. Buyers should be aware of this.

Who Might Still Consider NMN?

If you want to experiment despite the uncertainties: choose products with third-party certification (Labdoor, Informed Sport), prioritise purity and storage guidance (NMN is unstable at high temperatures), and calculate cost per daily dose — price differences of 5× for identical doses are not unusual.

Key Studies

Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice

de et al. (2016)

NMN raised NAD+ levels and improved vascular function in aged mice — no human trial.

PubMed PMID 26970090

Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men

Irie J et al. (2020) n=10

First human pilot study (n=10): NMN was safely absorbed and raised blood NAD+ metabolites. No clinical endpoints assessed.

PubMed PMID 31685720

Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice

Mills KF et al. (2016)

Classic animal study: NMN improved muscle function, energy metabolism, and insulin sensitivity in aged mice. Not transferable to humans.

PubMed PMID 28068222

Human whole-blood NAD+ levels do not vary with age or lifestyle interventions

Schmauck-Medina T et al. (2026)

Whole-blood NAD+ levels vary neither with age nor with lifestyle interventions — challenges the core assumption behind many NAD+ supplement claims.

PubMed PMID 42135539

NMN mitigates high-altitude hypoxia-induced cognitive impairment by inhibiting microglial ferroptosis

Xu Y et al. (2026)

Animal/cell study (no human trial): NMN inhibited ferroptosis in microglia via Sirt1/Nrf2/HO-1 signalling in hypoxia models. Mechanistically interesting, but not directly applicable to human supplementation.

PubMed PMID 42143976
Editorial notice: For most ingredients described here, no health claims are approved in the EU (Regulation (EC) 1924/2006). Evidence levels are editorial assessments of research quality — not health promises. This content is not a substitute for medical advice and does not constitute a recommendation to treat, alleviate, or prevent any disease.